

Revision date: 27-Nov-2016 Version: 2.1 Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: BeneFIX

Trade Name: BeneFIX

Synonyms: Recombinant Coagulation Factor IX; nonacog alfa

Chemical Family: Recombinant protein

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as blood clotting agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017

1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd

Ramsgate Road Sandwich, Kent CT13 9NJ

United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Warning

Hazard Statements: H317 - May cause an allergic skin reaction

May form combustible dust concentrations in air

Precautionary Statements: P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing must not be allowed out of the workplace P280 - Wear protective gloves/protective clothing/eye protection/face protection

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention P321 - Specific treatment (see supplemental first aid instructions on this label)

P363 - Wash contaminated clothing before reuse

P501 - Dispose of contents/container in accordance with all local and national regulations

Material Name: BeneFIX Page 2 of 8
Revision date: 27-Nov-2016 Version: 2.1



Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Glycine	56-40-6	200-272-2	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*
L-Histidine	71-00-1	200-745-3	Not Listed	*
Coagulation Factor IX	9001-28-9	232-594-4	Skin Sens. 1,H317	250-1000 IU/vial

Ingredient	CAS Number	EU	GHS Classification	%
		EINECS/ELINCS		
		List		
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safetv.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Material Name: BeneFIX Page 3 of 8
Revision date: 27-Nov-2016 Version: 2.1

Symptoms and Effects of

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure:

Identification and/or Section 11 - Toxicological Information.

Medical Conditions
Aggravated by Exposure:

None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion

Formation of toxic gases is possible during heating or fire.

Products:

Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning /

Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Glycine

Material Name: BeneFIX

Revision date: 27-Nov-2016

Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Latvia OEL - TWA 5 mg/m³

Sucrose

ACGIH Threshold Limit Value (TWA) 10 mg/m³ 10 ma/m³ **Australia TWA** 10 mg/m³ **Belgium OEL - TWA** 10.0 mg/m³ **Bulgaria OEL - TWA** Estonia OEL - TWA 10 mg/m³ France OEL - TWA 10 mg/m³ Ireland OEL - TWAs 10 mg/m³ Latvia OEL - TWA 5 mg/m³ Lithuania OEL - TWA 10 mg/m³ 15 mg/m³ **OSHA - Final PELS - TWAs:** 10 mg/m³ Portugal OEL - TWA 6 mg/m³ Slovakia OEL - TWA Spain OEL - TWA 10 mg/m³

L-Histidine

Latvia OEL - TWA 5 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective

Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:PowderColor:White to almost whiteOdor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:

Water Solubility:

PH:

Melting/Freezing Point (°C):

No data available

No data available.

No data available.

....

Material Name: BeneFIX Page 5 of 8
Revision date: 27-Nov-2016 Version: 2.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

Polysorbate 80
No data available
Coagulation Factor IX
No data available

Sucrose

No data available **L-Histidine**No data available

Glycine

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: May cause allergic reaction . Pharmaceutical blood clotting agent: may be fatal if injected or

enters bloodstream

Known Clinical Effects: This product contains protein of bovine origin. Those with known sensitivity should avoid

contact. Serious allergic reactions, including anaphylaxis, have been reported. Extensive intravascular clotting and death may result if injected or allowed to enter large blood vessels.

Acute Toxicity: (Species, Route, End Point, Dose)

Polysorbate 80

Material Name: BeneFIX

Revision date: 27-Nov-2016

Page 6 of 8

Version: 2.1

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 25 g/kg

Coagulation Factor IX

Mouse IP LD50 1000 ug/kg

Sucrose

Rat Oral LD50 29.7 g/kg

L-Histidine

Rat Oral LD 50 > 15 g/kg

Rat Para-periosteal LD 50 > 2g/kg Mouse Oral LD 50 > 15g/kg

Mouse Intravenous LD 50 > 2g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: BeneFIX
Revision date: 27-Nov-2016
Page 7 of 8
Version: 2.1

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Glycine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-272-2

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	

L-Histidine

EU EINECS/ELINCS List

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
FU FINECS/FLINCS List	200-745-3

Coagulation Factor IX

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	232-594-4

200-334-9

Material Name: BeneFIX Page 8 of 8
Revision date: 27-Nov-2016 Version: 2.1

15. REGULATORY INFORMATION

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal

Protection.

Revision date: 27-Nov-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet